AbbVie (ABBV) shares jump after Leerink Partners upgraded the stock to Outperform, saying the recent sell-off creates an opportunity for investors. The pharmaceutical stock tumbled earlier in the month after failing to meet the goals of its mid-stage trial for its schizophrenia drug, rivaling Bristol-Myers Squibb (BMY). Julie Hyman and Madison Mills break down what investors need to know.

To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

This post was written by Naomi Buchanan.